New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT04725474
First seen Jan 12, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study tests a new drug called visugromab (CTL-002) in people with advanced solid tumors that have stopped responding to standard treatments. The drug is given alone or together with an approved immunotherapy. The goal is to see if it is safe and can help shrink tumors. About 263 adults with various solid cancers are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universidad de Navarra, Unidad Central de Ensayos Clinicos
Pamplona, 31008, Spain
-
Hospital Universitari Vall d'Hebron, Institute of Oncology
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
ICMDiM, Hospital Clinic
Barcelona, 08036, Spain
-
ICO Hospitalet, Hospital Duran i Reynals
Barcelona, 08908, Spain
-
Kantonsspital St. Gallen, Clinic for Medical Oncology & Hematology
Sankt Gallen, 9007, Switzerland
-
Next Oncology, Phase I Unit. IOB - Hospital Quironsalud
Barcelona, 08023, Spain
-
START Madrid, Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
University Hospital Basel, Department for Medical Oncology
Basel, 4031, Switzerland
-
University Hospital Zurich, Department of Dermatology
Zurich, 9091, Switzerland
-
Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik
Essen, 45147, Germany
-
Universitätsklinikum Frankfurt, Medizinische Klinik I
Frankfurt am Main, 60590, Germany
-
Universitätsklinikum Würzburg, Comprehensive Cancer Center
Würzburg, 97078, Germany
Conditions
Explore the condition pages connected to this study.